The mRNA Platform: Speed and Precision
Before COVID-19, messenger RNA vaccines existed only in research laboratories. Within eighteen months of the SARS-CoV-2 sequence being published, mRNA vaccines had completed Phase 3 trials and received emergency authorization. This unprecedented timeline — compared to the typical decade-plus vaccine development process — demonstrated the transformative potential of the platform.
Traditional vaccines use weakened viruses, inactivated pathogens, or protein subunits to train immune systems. mRNA vaccines work differently: they deliver genetic instructions that prompt cells to temporarily produce a target protein, which the immune system then learns to recognize. No live pathogen is involved, and the mRNA degrades within days. The immune memory it creates, however, persists for years.
The key innovation making this possible came from decades of basic research by Katalin Karikó and Drew Weissman, who discovered in 2005 that chemically modifying nucleosides in mRNA prevented the inflammatory immune response that had previously made mRNA therapeutics impractical. This discovery, which earned the 2023 Nobel Prize in Physiology or Medicine, unlocked the entire platform.
